TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) December 13, 2022
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe December 1, 2022
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 15, 2022
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress October 14, 2022
